The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Failing the Public Health — Rofecoxib, Merck, and the FDA
Open accessAbstract
On May 21, 1999, Merck was granted approval by the Food and Drug Administration (FDA) to market rofecoxib (Vioxx). On September 30, 2004, after more than 80 million patients had taken this medicine and annual sales had topped $2.5 billion, the company withdrew the drug because of an excess risk of myocardial infarctions and strokes. This represents the largest prescription-drug withdrawal in history, but had the many warning signs along the way been heeded, such a debacle could have been prevented. Neither of the two major forces in this five-and-a-half-year affair — neither Merck nor the FDA — fulfilled its . . .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Cited by
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020124 · Cited by 10,505
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · CHANCE · doi:10.1080/09332480.2005.10722754 · Cited by 4,702
Chapter 4 European guidelines for the management of chronic nonspecific low back pain
Airaksinen, O., Brox, J. I., Cedraschi, C., Hildebrandt, J., Klaber-Moffett, J., Kovacs, F., Mannion, A. F., Reis, S., Staal, J. B., Ursin, H., et al. (2006) · European Spine Journal · doi:10.1007/s00586-006-1072-1 · Cited by 2,594
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Neuroinflammation: friend and foe for ischemic stroke
Jayaraj, R. L., Azimullah, S., Beiram, R., Jalal, F. Y., & Rosenberg, G. A. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1516-2 · Cited by 1,428
Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
Overall, C. M., & Kleifeld, O. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1821 · Cited by 1,214
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., & Taubert, K. A. (2007) · Circulation · doi:10.1161/circulationaha.106.181424 · Cited by 804
Transition from acute to chronic postsurgical pain: risk factors and protective factors
Katz, J., & Seltzer, Z. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.20 · Cited by 782
Guidelines for the clinical management of familial adenomatous polyposis (FAP)
Vasen, H. F. A., Möslein, G., Alonso, A., Aretz, S., Bernstein, I., Bertario, L., Blanco, I., Bülow, S., Burn, J., Capella, G., et al. (2008) · Gut · doi:10.1136/gut.2007.136127 · Cited by 704
Sackner-Bernstein, J. D., Kowalski, M., Fox, M., & Aaronson, K. (2005) · JAMA · doi:10.1001/jama.293.15.1900 · Cited by 693
Are animal models predictive for humans?
Shanks, N., Greek, R., & Greek, J. (2009) · Philosophy, Ethics, and Humanities in Medicine · doi:10.1186/1747-5341-4-2 · Cited by 677
Ibuprofen: pharmacology, efficacy and safety
Rainsford, K. D. (2009) · Inflammopharmacology · doi:10.1007/s10787-009-0016-x · Cited by 667
Osteoarthritis — an untreatable disease?
Wieland, H. A., Michaelis, M., Kirschbaum, B. J., & Rudolphi, K. A. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1693 · Cited by 585
The Truth About Drug Companies: How They Deceive Us and What to Do About It.
Henderson, S. W. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000157547.41337.46 · Cited by 506
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2019) · CHANCE · doi:10.1080/09332480.2019.1579573 · Cited by 463
Reporting bias in medical research - a narrative review
McGauran, N., Wieseler, B., Kreis, J., Schüler, Y.-B., Kölsch, H., & Kaiser, T. (2010) · Trials · doi:10.1186/1745-6215-11-37 · Cited by 452
Intraarticular drug delivery in osteoarthritis☆
GERWIN, N., HOPS, C., & LUCKE, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.01.018 · Cited by 442
Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity
Kawano, T., Anrather, J., Zhou, P., Park, L., Wang, G., Frys, K. A., Kunz, A., Cho, S., Orio, M., & Iadecola, C. (2006) · Nature Medicine · doi:10.1038/nm1362 · Cited by 374
Rostom, A., Dubé, C., Lewin, G., Tsertsvadze, A., Barrowman, N., Code, C., Sampson, M., & Moher, D. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-5-200703060-00010 · Cited by 343
Alzheimer's Disease and Mild Cognitive Impairment
Kelley, B. J., & Petersen, R. C. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.03.008 · Cited by 326
Outcome of non-invasive treatment modalities on back pain: an evidence-based review
van Tulder, M. W., Koes, B., & Malmivaara, A. (2006) · European Spine Journal · doi:10.1007/s00586-005-1048-6 · Cited by 313
Cannabinoids in the management of difficult to treat pain
Russo, E. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s1928 · Cited by 294
Pharmacovigilance: methods, recent developments and future perspectives
Härmark, L., & van Grootheest, A. C. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0475-9 · Cited by 289
Mitchell, J. A., & Warner, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1929 · Cited by 279
Cyclooxygenase 2 Plays a Pivotal Role in the Resolution of Acute Lung Injury
Fukunaga, K., Kohli, P., Bonnans, C., Fredenburgh, L. E., & Levy, B. D. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.5033 · Cited by 275
Zhou, S.-F., Wang, B., Yang, L.-P., & Liu, J.-P. (2010) · Drug Metabolism Reviews · doi:10.3109/03602530903286476 · Cited by 262
Interleukin-1β has atheroprotective effects in advanced atherosclerotic lesions of mice
Gomez, D., Baylis, R. A., Durgin, B. G., Newman, A. A. C., Alencar, G. F., Mahan, S., St. Hilaire, C., Müller, W., Waisman, A., Francis, S. E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0124-5 · Cited by 256
Abassi, Y. A., Xi, B., Zhang, W., Ye, P., Kirstein, S. L., Gaylord, M. R., Feinstein, S. C., Wang, X., & Xu, X. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.05.011 · Cited by 254
Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies
Papanikolaou, P. N. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.050873 · Cited by 229
Publication of Clinical Trials Supporting Successful New Drug Applications: A Literature Analysis
Lee, K., Bacchetti, P., & Sim, I. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050191 · Cited by 215
“A string of recent controversies concerning the suppression of safety risks of rosiglitazone [6], paroxetine [7], and rofecoxib [8,9] has drawn public attention to the limited and incomplete public access to clinical trial results on FDAapproved drugs [10] and has resulted in a concerted effort to achieve improved com…”
BackgroundAcademic Medical Centers' Standards for Clinical-Trial Agreements with Industry
Mello, M. M., Clarridge, B. R., & Studdert, D. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa044115 · Cited by 132
De Caterina, R., & Massaro, M. (2005) · Journal of Membrane Biology · doi:10.1007/s00232-005-0783-2 · Cited by 130
Evolution and Translation of Research Findings: From Bench to Where
Ioannidis, J. P. A. (2006) · PLoS Clinical Trials · doi:10.1371/journal.pctr.0010036 · Cited by 129
Adverse events: the more you search, the more you find
Ioannidis, J. P. A., Mulrow, C. D., & Goodman, S. N. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-4-200602210-00013 · Cited by 69
Carlson, N. G., Hill, K. E., Tsunoda, I., Fujinami, R. S., & Rose, J. W. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.01.008 · Cited by 42
Metadata
- Authors
- Topol, E. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-10-21
- Volume
- 351
- Issue
- 17
- Pages
- 1707-1709
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1965992514
- Cited by
- 599
- References
- 2
- FWCI
- 83.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.